Showing 1 - 5 results of 5 for search 'Gerald S Falchook', query time: 0.03s
Refine Results
-
1
B7-H3 Inhibitors in Oncology Clinical Trials: A Review by Kavanya Feustel, Jared Martin, Gerald S. Falchook
Published 2024-02-01
Article -
2
Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers by Martin V. Nguyen, Lydia Loof, Gerald S. Falchook
Published 2020-02-01
Article -
3
Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials by Haelee M Chin, David K Lai, Gerald S Falchook
Published 2019-02-01
Article -
4
736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies by Mario Sznol, Harriet Kluger, Igor Puzanov, Gerald S Falchook, Ryan Sullivan, Matthew H Taylor, Justin C Moser, Aaron M Ring, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen
Published 2023-11-01Article -
5
759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors by Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore
Published 2023-11-01Article